Skip to content Skip to left sidebar Skip to right sidebar Skip to footer

Tag: #HealthcareInnovation

Amgen to Establish New Science and Innovation Centre in Hyderabad’s Genome Valley

Global biopharmaceutical giant Amgen is doubling down on its commitment to India, announcing plans to open a state-of-the-art Science and Innovation Centre in Hyderabad’s premier Genome Valley. Slated to become operational in 2027, this new facility will mark a significant expansion of Amgen’s global research and development (R&D) network, which currently comprises seven research laboratories worldwide.

Bridging Wet-Lab Science and Digital Innovation

The new Hyderabad centre is designed to be a powerhouse of discovery. It will focus on critical, high-impact areas including:

  • Discovery Chemistry
  • Drug Metabolism and Pharmacokinetics (DMPK)
  • Precision Medicine
  • Data Science and Digital Technologies

By integrating experimental “wet-lab” science with advanced data analytics and AI-driven tools, the centre aims to dramatically accelerate the discovery and development of life-saving medicines. This facility will seamlessly complement Amgen’s existing Global Capability Centre (GCC) in Hyderabad, creating a powerful synergy between digital innovation and hands-on biological research.

Why Hyderabad? A Thriving Life Sciences Ecosystem

Hyderabad has long been recognized as India’s “Genome Valley,” but this new investment signals a shift from manufacturing and clinical research to high-value, early-stage discovery.

D. Sridhar Babu, Telangana’s Minister for IT and Industries, praised the decision, highlighting the state’s robust ecosystem: “Hyderabad brings together scientific talent, technology, and industry at scale and has built one of the world’s strongest life sciences ecosystems, with deep capabilities in pharmaceuticals and vaccines. The next chapter is about taking that strength into discovery and innovation. Our ambition is to make Hyderabad a place where the next generation of medicines and therapies can be discovered, developed, and taken to the world.”

Leadership Perspectives on Global Integration

For Amgen, this move is about creating a truly interconnected global R&D footprint.

Jay Bradner, Executive Vice President of Research and Development, Artificial Intelligence, and Data at Amgen, noted that the Genome Valley centre will perfectly complement the company’s strong US-based R&D operations. It will expand Amgen’s ability to connect science, data, and technology across its global research system, translating complex insights into tangible new medicines.

Som Chattopadhyay, Senior Vice President of Global Business Solutions and National Executive at Amgen, emphasized that this development firmly establishes India as a critical, strategic pillar in Amgen’s global R&D network.

Echoing this sentiment, Naveen Gullapalli, Managing Director of Amgen India, highlighted the region’s human capital: “Hyderabad’s STEM talent and life sciences ecosystem will support advanced technologies at scale. Our new centre at Genome Valley will help integrate biotechnology and digital innovation to serve more patients globally.”

Looking Ahead

Amgen’s investment in Hyderabad is a resounding vote of confidence in India’s scientific prowess and its potential to drive global healthcare innovation. As the centre gears up for its 2027 launch, it promises to create high-value jobs, foster cutting-edge research, and cement Hyderabad’s status as a premier global destination for biotech discovery and digital health innovation.

The future of medicine is being written in Hyderabad, and Amgen is ready to lead the next chapter.

ISCSGCON 2026 Stem Cell Conference Concludes in Hyderabad

The 8th International Conference on Stem Cells (ISCSGCON-2026) successfully concluded in Hyderabad, bringing together leading scientists, clinicians, and researchers from across India and other countries. The event served as an important platform to discuss the latest developments in stem cell research and regenerative medicine.

The two-day conference featured participation from more than 50 experts in the field, who shared insights into innovative treatment methods, ongoing research, and future applications of stem cell therapies. Experts highlighted how regenerative medicine is transforming healthcare by offering new approaches to repair or replace damaged tissues and organs.

One of the major highlights of the conference was the live demonstrations of advanced regenerative procedures, giving attendees an opportunity to observe modern treatment techniques and understand how these therapies are applied in clinical practice.

The conference was jointly organized by the Indian Stem Cell Study Group (ISCSG) and Yashoda Hospitals, with several medical professionals and researchers participating in discussions and workshops. The event also focused on strengthening collaboration between scientists, healthcare professionals, and researchers working in regenerative medicine.

Experts at the conference noted that such scientific gatherings help strengthen Hyderabad’s position as an emerging hub for biomedical research and medical innovation. The event also encouraged knowledge sharing and collaboration that could contribute to future medical breakthroughs.

Sanofi Expands Hyderabad GCC, Adds Nearly 2,000 Jobs in India

French pharmaceutical giant Sanofi is deepening its commitment to India with a major expansion of its Global Capability Centre (GCC) in Hyderabad. The company plans to add nearly 2,000 new jobs, increasing total headcount at the centre from over 2,600 employees to more than 4,500 professionals.

The expansion reflects Sanofi’s long-term strategy to strengthen its global operations by leveraging India’s growing pool of high-skilled talent in research, technology, and digital innovation.

Significant Investment to Support Growth

The expansion will be backed by a multi-hundred-million-dollar investment, though the company has not specified an exact hiring timeline. This move builds on Sanofi’s 2024 commitment to invest €400 million (approximately $474.6 million) in its India GCC operations by the end of the decade.

The investment signals a shift toward scaling high-value functions in India, positioning the Hyderabad centre as a critical part of Sanofi’s global ecosystem.

Focus on Innovation and Advanced Capabilities

The additional roles will span across several strategic domains, including:

  • Research & Development (R&D)
  • Artificial Intelligence (AI)
  • Data Innovation and Analytics
  • Medical Affairs
  • Commercial Capabilities
  • Corporate Functions

This indicates that Sanofi’s Hyderabad centre is evolving beyond traditional support services into a global innovation hub that contributes directly to enterprise-wide strategy and transformation.

India’s Growing GCC Ecosystem

Sanofi’s expansion comes at a time when India’s Global Capability Centre ecosystem is witnessing rapid growth. According to Anarock:

  • India hosts more than 1,700 GCCs
  • These centres employ over 1.9 million professionals
  • The GCC market could grow to $105–110 billion by 2030
  • The number of centres may exceed 2,400 by the end of the decade

What were once considered cost-efficient back-office operations have now transformed into innovation-led centres driving digital transformation, R&D, finance, and global operations.

Hyderabad: A Strategic Pharma Hub

Hyderabad has increasingly become a focal point for global life sciences and technology companies. The announcement precedes the city’s flagship biotechnology conference, BioAsia, where global pharmaceutical leaders such as Eli Lilly, Novo Nordisk, Merck, and Sanofi are expected to discuss research expansion and India’s pharmaceutical growth trajectory.

The timing further underscores Hyderabad’s growing importance in global healthcare innovation.

A Strategic Shift in Global Operations

For Sanofi, the Hyderabad GCC is emerging as a cornerstone of its global strategy. As pharmaceutical companies rebalance supply chains and invest heavily in digital capabilities, India’s skilled workforce and strong ecosystem make it a preferred destination for long-term investment.

This expansion not only strengthens Sanofi’s operational capabilities but also reinforces India’s position as a global hub for advanced research, AI, and pharmaceutical innovation.

US–Hyderabad Symposium Highlights Shared Solutions for Innovation, Equity and Sustainability

Hyderabad:
Illinois State Senator Laura Murphy said governments across the world face similar challenges and stressed that real progress lies not in reinventing solutions, but in removing barriers that prevent proven ideas from being implemented. She was speaking at the USA–Hyderabad Symposium on “Bridges of Innovation: Technology and Interfaith Partnerships”, jointly organized by CMMA, WWMI, University of Florida, and Media Plus Foundation, held at the historic Nizam Club.

Calling her first visit to India a memorable and enriching experience, Senator Murphy praised the country’s warmth, culture, and hospitality, and said she was deeply honoured by the welcome extended to the US delegation. Emphasising people-centric governance, she highlighted equity in education and access to information as key foundations for effective policymaking.

Illinois State Representative Anna Moeller noted that the United States has grown stronger due to immigrants who brought ideas, ambition, and hard work. She said India has made immense contributions to the US, particularly through the South Asian community, and cautioned that restricting borders and limiting the exchange of ideas would hinder long-term progress.

Dr Tajammul Hussain, President of CMMA and Chief of Oncology, Chicago, called for deeper cross-border collaboration, urging professionals such as doctors, engineers, and technologists to move beyond narrow roles and embrace broader humanitarian responsibilities.

Speaking on urban resilience, John Mahyer, Vice President of Engineering Resources Associates, USA, shared effective stormwater management strategies currently used by US state governments and municipalities.

Indian-American AI healthcare specialist Dr Srikanth Mahankali spoke on artificial intelligence in healthcare, stressing the need for responsible innovation to maintain public trust. He cautioned against over-dependence on AI, stating that nearly 60% of people in the US prefer human involvement over AI in healthcare.

The symposium was attended by Prof. H. Sandhu (University of Florida), Engineer M.A. Nayeem (Chairman, Masah Construction), Sam Pappu (President, WWMI), Khaja Mohiuddin (Vice President, WWMI), senior architect Ameera Ashraf O’Neil, Syed Khaled Shahbaaz (CEO, Media Plus), and other dignitaries.